320 related articles for article (PubMed ID: 34083030)
61. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
62. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
63. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
[TBL] [Abstract][Full Text] [Related]
64. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
65. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism.
Søgaard M; Nielsen PB; Skjøth F; Kjældgaard JN; Coleman CI; Larsen TB
Am J Med; 2018 Jul; 131(7):787-794.e4. PubMed ID: 29476744
[TBL] [Abstract][Full Text] [Related]
66. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
67. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
68. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
69. National Trends in Ambulatory Oral Anticoagulant Use.
Barnes GD; Lucas E; Alexander GC; Goldberger ZD
Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101
[TBL] [Abstract][Full Text] [Related]
70. Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism.
Lutsey PL; Zakai NA; MacLehose RF; Norby FL; Walker RF; Roetker NS; Adam TJ; Alonso A
Br J Haematol; 2019 Jun; 185(5):903-911. PubMed ID: 30919942
[TBL] [Abstract][Full Text] [Related]
71. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
72. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Imberti D; Pomero F; Mastroiacovo D
Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
[TBL] [Abstract][Full Text] [Related]
73. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
[TBL] [Abstract][Full Text] [Related]
74. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
75. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
76. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
[TBL] [Abstract][Full Text] [Related]
77. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
Comerota AJ; Ramacciotti E
Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
[TBL] [Abstract][Full Text] [Related]
78. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
79. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
80. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
